PCORI Continues to Come Under Scrutiny
As policy makers continue to examine the best methods for controlling the costs of health care, one of the lead supporters of comparative effectiveness research (CER) is voicing concerns that the Patient Centered Outcomes Research Institute (PCORI) is lacking the sense of urgency to tackle high-impact clinical questions.
In an article published in Health Affairs, Harold Sox, who co-chaired the 2009 Institute of Medicine panel on CER, argued that due to the slow pace of clinical research, there are threats to PCORI being reauthorized beyond the sunset date of September 2019 set by the Affordable Care Act.
MDMA recently submitted comments with our members input on PCORI's draft methodology that is intended to guide health care stakeholders towards the best and most appropriate methods for conducting CER.
MDMA noted that PCORI should support research on wellness and prevention to complement its current thinking on CER, pointing to the growing trend of obesity in the U.S. as a key driver of health care costs.
"If our country continues on this path, we can only begin to try to speculate what the related costs will be for treating obesity related conditions, such as diabetes, pulmonary hypertension and heart disease in general," wrote MDMA.
MDMA continues our work with the Administration and Members of Congress to improve the CER program and other parts of the health care reform legislation that could harm innovation.